Angiotensin II induces histomorphologic features of unstable plaque in a murine model of accelerated atherosclerosis  by da Cunha, Valdeci et al.
BASIC RESEARCH STUDIES
Angiotensin II induces histomorphologic features
of unstable plaque in a murine model of
accelerated atherosclerosis
Valdeci da Cunha, PhD,a Baby Martin-McNulty, BS,a Jon Vincelette, BS,a David F. Choy, BS,a
We-Wei Li, PhD,a Miriam Schroeder, BS,a Mithra Mahmoudi, MS,a Meredith Halks-Miller, MD,a
Dennis W. Wilson, PhD,b Ronald Vergona, PhD,a Mark E. Sullivan, PhD,a and
Yi-Xin (Jim) Wang, MDa Richmond and Davis, Calif
Background: We explored the role of angiotensin II in determining the histomorphometric features of plaque stability in
apolipoprotein E–deficient mice submitted to ligation of the carotid artery.
Methods: Six-month-old apolipoprotein E–deficient mice underwent ligation of the common left carotid artery and were
immediately assigned to receive either angiotensin II (1.4 mg · kg1 · d1 subcutaneously) or vehicle (phosphate-buffered
saline; control) via a subcutaneous osmotic minipump for 4 weeks.
Results: Ligated arteries from control animals developed intimal lesions composed of macrophage foam cell plaques,
which accumulated adjacent to the internal elastic lamina and were surrounded by a fibromuscular layer. Angiotensin
II–treated mice had a greater intimal area (threefold), which was accompanied by a fivefold increase in the foam cell area.
Lesions from angiotensin II–treated mice also displayed complex morphology characterized by intralesional neovascula-
ture and hemorrhage. The content of active matrix metalloproteinase 2, mainly colocalized with macrophage foam cells,
and the production of the inflammatory mediators monocyte chemoattractant protein 1 and vascular cell adhesion
molecule 1 were also increased by angiotensin II treatment. Although angiotensin II induced vessel expansion and lumen
loss to a similar extent, only vessel enlargement correlated with intimal area.
Conclusions: Taken together, this study’s results support a role of angiotensin II in plaque vulnerability by promoting
intraplaque neovascularization/hemorrhage, inflammation, and expansive remodeling. (J Vasc Surg 2006;44:364-71.)
Clinical Relevance: In this study, we assessed the effect of angiotensin II on histomorphologic features of unstable plaques
in the carotid ligation model in mice. We chose an animal model with two important features of human atherosclerosis
development: the presence of an intact endothelial layer and an altered hemodynamic environment. Related to these
features, macrophage-rich intimal lesions in ligated carotid arteries are associated with outward or expansive remodeling
of the vessel, the hallmark of unstable plaques. In addition, to show the effect of angiotensin II on lesion features, our data
further strengthen the concept that expansively remodeled plaques represent an unstable phenotype.A variety of clinical and experimental studies support a
role for angiotensin II in the progression of atherosclero-
sis.1-4 Regardless, it remains to be determined whether
angiotensin II acts as an accelerating factor only or as a
modifier of the lesion with an effect on plaque vulnerability.
In this regard, studies aimed at localizing angiotensin II in
human atherosclerotic lesions have yielded inconclusive
results. For instance, although the results by Schieffer et al5
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364suggest a contributory role for angiotensin II in the inflam-
matory processes of ruptured plaques, recent observations
by Morioka et al6 indicate that intraplaque angiotensin II
expression is associated with the proliferation of smooth
muscle cells (SMCs) and, therefore, contributes to plaque
stability. Similarly, experimental studies have shown that
angiotensin II either induces histologic changes to a vul-
nerable phenotype7 or accelerates plaque formation with-
out a noticeable change in its composition.8,9 Moreover,
we have observed that lesions in the aortic arch from
angiotensin II–treated apolipoprotein E–deficient (apoE-
KO) mice display a significant fibrohistiocytic layer cover-
ing foam cell plaques, featuring a fibrous and stable
plaque.10
Plaque vulnerability/stability is also closely associated
with the mode of arterial remodeling that accompanies
lesion development. Arteries undergo expansive remodel-
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plaque accumulation turns the geometric remodeling re-
sponse into a constrictive mode, an important determinant
of lumen loss.11 Although expansive remodeling compen-
sates for plaque growth and temporarily prevents lumen
loss, expansively remodeled atherosclerotic vessels often
give rise to more rupture-prone lesions (large lipid core and
thin fibrous cap) than those undergoing constrictive re-
modeling.12 The mechanisms linking plaque vulnerability
and expansive remodeling remain to be fully established
and may involve macrophage/foam cell activation.13
Therefore, early expansive remodeling can be used as an
indicator of later plaque rupture. Because animal models do
not mimic all features of human unstable atherosclerotic
lesions, the evaluation of the mode of vascular remodeling,
in association with histologic markers, creates a better
model for assessing plaque vulnerability. In this regard,
Ivan et al14 showed that the ligation of carotid arteries in
apoE-KOmice creates a model of accelerated atherosclero-
sis in which intimal macrophage foam cell content is asso-
ciated with expansive remodeling, a marker of unstable
plaques. Therefore, this study was designed to explore the
effect of angiotensin II in inducing histomorphologic fea-
tures of plaque stability by assessing lesion composition and
geometric vascular remodeling after carotid artery ligation
in apoE-KO mice.
METHODS
Surgery. Six-month-old male apoE-KO mice (The
Jackson Laboratory, Bar Harbor, Me) fed a normal chow
were used in this study. With mice under anesthesia (isoflu-
rane, 2%-3% inhalation), the left carotid artery was exposed
through a midline incision in the neck. The artery was
completely ligated near its bifurcation by using a 5-0 silk
suture. The right carotid artery was used as a self-control,
by placing a nonligating suture around it. At the time of
ligation, animals were randomly assigned to subcutaneous
implantation of a minipump filled with either angiotensin
II (1.44 mg · kg1 · d1) or phosphate-buffered saline
(control). We chose an infusion rate of angiotensin II
previously shown to accelerate atherosclerosis in apoE-KO
mice.2,10 Thirty days after carotid ligation, blood was with-
drawn, and animals were killed. The arteries were excised
and sectioned for histological analysis, frozen (80° C) for
matrix metalloproteinase (MMP)-2 activity assay, or incu-
bated for monocyte chemoattractant protein (MCP)-1 and
vascular cell adhesion molecule (VCAM)-1 determination.
All animal protocols were approved by the Institutional
Animal Care and Use Committee.
Blood pressure and lipid determination. Because of
the consistency of blood pressure values and lipid levels in
our previous studies involving angiotensin II treatment in
apoE-KO mice, these parameters were evaluated in a ran-
domized subgroup of animals (n  6 per group). On the
day before the animals were killed, blood pressure was
measured in conscious mice by using a tail-cuff system
(Hatteras Instruments, Inc, NC).Total cholesterol and triglycerides were measured in
serum from overnight fasting mice by a clinical laboratory
(IDEXX, Sacramento, Calif) using commercially available
kits (total cholesterol with Cholesterol Assay Kit [Equal
Diagnostics]; triglycerides with Triglycerides/GPO kit
[Roche Diagnostics]).
Morphometric analysis and immunohistochemistry.
In previous studies, we observed that the morphology of
ligated vessels fixed by immersion15 is similar to that ob-
tained under perfusion pressure.16 In addition, perfusion-
pressure fixationmight not be a straightforwardmethod for
experimental groups with different levels of blood pressure.
Therefore, in this study, the carotid arteries were removed
en bloc, immersed in 10% buffered formalin, and then
embedded in paraffin. Sections (5 m) from the middle
portion (approximately 3 mm away from the ligation) of
both vessels stained with hematoxylin and eosin were used
for morphometry and morphology evaluation, according
to a previous study.17 Contours of the lumen, internal
elastic lamina (IEL), external elastic lamina (EEL), and
adventitial layer, when present (a tightly packed agglomer-
ate of cells surrounding EEL), were traced on digitized
images by using a computer-based morphometric analyz-
ing system (Computer Assisted Stereology Toolbar; Olym-
pus Denmark, Denmark). Vessel and lumen diameters,
defined as EEL perimeter/ and lumen perimeter/, re-
spectively, were calculated assuming that all vessels have a
circular morphology. The adventitial area represents the
area between the EEL and the outer edge of tightly packed
adventitial cells. The medial area represents the area be-
tween the EEL and IEL, and the intimal lesion area was
calculated by subtracting the lumen area from the IEL area.
The Computer Assisted Stereology Toolbar system was
also used to quantify the area occupied by foam cells by
tracing the contours of cell agglomerates. Intimal fat accu-
mulation was visualized by Oil Red O staining on represen-
tative longitudinally opened arteries.18
For immunohistochemical analysis, sections were
stained for smooth muscle -actin (DAKO monoclonal
smooth muscle -actin clone 1A4; 1:100 dilution), macro-
phage MAC-3 (BD Pharmingen rat anti-mouse macro-
phage MAC-3; 1:250 dilution), and MMP-2 (Chemicon
rabbit polyclonal MMP-2 AB809; 1:1000 dilution). For
negative controls, nonimmune immunoglobulin G was
used as the primary antibody. The presence of -actin–
positive and MAC-3–positive cells was evaluated in a semi-
quantitative manner with a grading system from 0 to 4 by
a researcher unaware of the sample identity, as previously
described.19
MMP-2 activity and soluble MCP-1 and VCAM-1
production. For MMP-2 activity measurement, arteries
(five control and four angiotensin II–treated mice) were
homogenized individually in 400 L of Tris buffer (50
mmol/L Tris, 1 mmol/L ethylenediaminetetraacetic acid,
1% Triton, and protease inhibitor cocktail). After homog-
enization, the tissue suspension was spun at 3000 rpm for
10 minutes, and the supernatant was frozen at 80° C
until assayed. MMP-2 activity was measured by using a
JOURNAL OF VASCULAR SURGERY
Augutst 2006366 da Cunha et alcommercially available kit (Biotrak Amersham Biosciences)
that specifically recognizes active MMP-2. The assay sensi-
tivity is 0.19 ng/mL. Results are expressed as nanograms
per milligram of tissue.
Fig 1. Cross-sectional areas of adventitial (A), medial (B), and
intimal (C) layers of ligated arteries from control and angiotensin
II–treated mice. Bars represent mean  SEM. *P  .05. Ang,
Angiotensin.
Fig 2. Vessel diameter (A) of ligated arteries from contr
respective intimal area (B). Lumen diameter of ligated art
correlation with the respective intimal area (D). Bars r
measurements. *P  .05. Ang, Angiotensin.For MCP-1 and VCAM-1 measurements, freshly re-
moved carotid arteries were incubated in 300 L of mini-
mum essential medium at 37° C for 24 hours. MCP-1 and
VCAM-1 levels were measured in the supernatant by using
ELISA kits (R&D Systems, Minneapolis, Minn). The sen-
sitivities of the assays forMCP-1 and VCAM-1 are 2 and 30
pg/mL, respectively. Results are expressed as nanograms
per milligram of tissue.
Statistical analysis. The results are presented as mean
 SEM. Statistical significance was established by using the
unpaired Student t test with equal variances at P  .05.
RESULTS
Body weight was comparable in both groups before
treatment (control, 31 1 g; angiotensin II, 33 1 g) and
at the end of treatment (control, 30  1 g; angiotensin II,
30  1 g). Systolic blood pressure was significantly higher
in angiotensin II–treated mice (166  7 mm Hg) than in
control mice (110 5mmHg). At death, control mice had
a total serum cholesterol level of 648  51 mg/dL and a
triglycerides level of 234 40 mg/dL, and these were not
significantly different in angiotensin II–treated mice (cho-
lesterol, 708  22 mg/dL; triglycerides, 317  58 mg/
dL).
Effect of angiotensin II on vessel wall morphology.
Nonligated carotid arteries from both groups displayed
fibrous-fatty lesions only proximal to the aortic arch and
close to the bifurcation, as previously demonstrated.20,21
At the level (middle portion) chosen for this analysis,
angiotensin II–treated mice and its correlation with the
from control and angiotensin II–treated mice (C) and its
ent the mean  SEM, and circles represent individualol and
eries
epres
JOURNAL OF VASCULAR SURGERY
Volume 44, Number 2 da Cunha et al 367normal histology without atherosclerotic lesions was found
in all nonligated arteries from both groups. The area of
individual layers (adventitial, medial, and intimal) of ligated
arteries is shown in Fig 1. Adventitial proliferation occurred
outside the EEL and was characterized by circumferentially
oriented accumulation of elongate cells with spindle-
shaped nuclei embedded in a fibrillar matrix with admixed
MAC-3–positive mononuclear cells. This change was
found in ligated arteries from both groups, and the area was
significantly greater in the angiotensin II–treated group.
The medial area, however, was not different between the
two groups. Ligated vessels also displayed an intimal area in
both groups, although it was significantly larger (threefold
increase) in angiotensin II–treated animals. As shown in Fig
2, an increase in vessel diameter and a decrease in lumen
diameter were observed in angiotensin II–treated animals
compared with control animals. A strong correlation be-
tween vessel enlargement and intimal area was found in
ligated arteries from both groups (Fig 2, B), contrasting
with a nonsignificant correlation between lumen diameter
Fig 3. Cross-sectional foam cell area (A) and semiquan
(C) areas in the intima of ligated arteries from control
SEM. *P  .05. En face ligated carotid arteries from r
stained with Oil Red O (D). Ang, Angiotensin.and intimal area (Fig 2, D).Effect of angiotensin II on cell composition. The
effect of angiotensin II in augmenting neointima formation
in ligated arteries included a fivefold increase in the area of
intima occupied by foam cells (Fig 3, A). In both groups,
intimal lesions were characterized by the presence of mac-
rophage foam cell plaques (MAC-3–positive cells) immedi-
ately adjacent to the IEL that were overlain by a fibromus-
cular layer (-actin–positive cells). The intimal area
occupied by SMCs (-actin staining) and nonfoamy mac-
rophages (MAC-3 staining) infiltrating the muscular layer
was also increased by angiotensin II (Fig 3, B and C).
However, the ratio of -actin/MAC-3 staining was not
significantly different between the two treatments (control,
1.2 0.1; angiotensin II, 1.7 0.3). Lipid accumulation,
as observed from the en face preparations, occupied a larger
area and was more intensely stained with Oil Red O in the
arteries of the angiotensin II–treated group (Fig 3, D).
Figure 4 shows representative sections of ligated arteries
from control and angiotensin II–treated mice stained with
hematoxylin and eosin and immunostained for macro-
ve analysis of -actin–positive (B) and MAC-3–positive
ngiotensin II–treated mice. Bars represent the mean 
entative control and angiotensin II–treated mice weretitati
and a
epresphages (MAC-3) and SMCs (-actin).
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mice included well-developed intralesional neovasculature
and hemorrhage (Fig 5). Aggregates of erythrocytes, ran-
domly dissected fibromuscular cells in the intima, and
occasional aggregates of hemosiderin were evident. In
some foci, cleftlike spaces containing erythrocytes were
lined by endothelial cells. Intimal hemorrhage was not
evident in control mice, and limited neovessel formation
Fig 4. Representative sections of ligated arteries from control
(upper) and angiotensin II–treated (lower)mice were stained with
hematoxylin and eosin and immunostained for macrophages
(MAC-3) and smooth muscle cells (SMCs; -actin). Intimal le-
sions were characterized by macrophage foam cells adjacent to the
internal elastic lamina surrounded by proliferating SMCs. Note the
larger foam cell plaque and thicker fibromuscular layer in the lesion
from an angiotensin II–treated mouse. Nonfoamy macrophages
were also present within SMC-rich regions in both groups. The
artery from the angiotensin II–treated animal underwent signifi-
cant enlargement in relation to the control, as evidenced by the
stretched aspect of the elastic laminae. Such an alteration in the
morphology of the elastic laminae is not an artifact of the fixation
method, because it was consistently found in all vessels with large
intimal areas, in agreement with previous observations.15 Addi-
tional findings in angiotensin II–treated mice included a thicker
neoadventitial area. Ang, Angiotensin.was present in only one of six vessels.Effect of angiotensin II on active MMP-2 levels.
Figure 6 shows active MMP-2 levels in the homogenates of
freshly removed arteries; these levels were significantly
higher in angiotensin II–treated arteries. Immunostaining
for MMP-2 revealed strong colocalization with foam cell
macrophages lining the internal elastic layer.
Effect of angiotensin II on MCP-1 and VCAM-1
production. Protein release after 24 hours of incubation
for both MCP-1 (control: 0.3  0.2 ng/mg, n  10;
angiotensin II: 1.6  0.2 ng/mg, n  10; P  .05) and
VCAM-1 (control: 0.1 0.1 ng/mg, n 10; angiotensin
II: 0.82 0.18 ng/mg, n 10; P .05) was significantly
increased in ligated arteries from angiotensin II–treated
mice.
DISCUSSION
The main findings of this study are as follows: (1) carotid
artery ligation of hypercholesterolemic mice was associated
with a rapid development of intimal fibrous-fatty lesions,
which were accelerated by angiotensin II; (2) angiotensin II
treatment also increased plaque complexity by inducing in-
tralesional hemorrhage and neovascularization; (3) the con-
tent of active MMP-2, an important mediator of matrix de-
struction, and the production of the inflammation-related
mediators MCP-1 and VCAM-1 were also increased by an-
giotensin II treatment; and (4) although angiotensin II pro-
portionally both induced the expansion of vessel size and
decreased the lumen diameter, only vessel enlargement corre-
Fig 5. (Upper panel) A thickened intima from a control animal
displaying smooth muscle cells in a matrix background is shown
(different regions of the vessel). Note the presence of rare small
intralesional vessels (open arrow). (Lower panel) Advanced lesions
in angiotensin II–treated mice display a more complex morphol-
ogy characterized by large and more irregular intralesional vessels
(marked by an open arrow) and the presence of intralesional
erythrocytes (thin arrow) and hemosiderin (thick arrow), which
are indicators of recent and previous hemorrhage.lated with intimal area.
giote
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depends on a variety of factors, such as the mass of the lipid
core, the thickness of the atheromatous fibrous cap, and the
presence of activated macrophages in the fibrous cap.22
Experimental atherosclerosis has been successfully induced
in several animal species with results that have significantly
added to the understanding of the pathobiologic mecha-
nisms of the disease. Atherosclerotic lesions in hypercho-
lesterolemic animals resemble some, but not all, aspects of
the human condition.23-26 Although complex lesions have
been described in aging animals,27 plaque rupture has been
limited to the brachiocephalic artery of apoE-KO mice fed
a high-fat diet.28 Evidence indicates that the modifying
factors of plaque stability are also responsible for determin-
ing the remodeling mode of the atherosclerotic vessel.
Confirming human pathology studies linking inflammation
to plaque instability and expansive remodeling,13 a recent
study found a positive correlation between intimal macro-
phage accumulation and expansive remodeling in ligated
carotid arteries of apoE-KO mice.14 In this model, reduced
blood flow and, consequently, reduced endothelial shear
stress are considered to be the primary mechanism under-
lying intimal hyperplasia development.17 This is a desirable
feature for an animal model because regions with low
endothelial shear stress coincide with sites of atheroscle-
rotic lesions in humans.29
In our study, ligation of the carotid artery led to accu-
mulation of a fibrous-fatty lesion in the intima, and this was
associated with expansive remodeling of the arterial wall.
Fig 6. A, Quantitative determination of active matrix m
carotid arteries from control and angiotensin II–treated
immunostaining and hematoxylin and eosin staining in r
and angiotensin II–treatedmice. Themost pronounced a
adjacent to the IEL, as indicated by the arrows. Ang, AnThe accelerating effect of angiotensin II on neointimallesion formation was also associated with more complex
lesions. Advanced lesions in the angiotensin II–treated
group had extensive areas infiltrated with erythrocytes and
deposits of hemosiderin, indicators of recent and previous
hemorrhage and evidence of neovascularization. Multiple
studies underscore a critical link between intralesional hem-
orrhage and plaque growth and instability by stimulating
macrophage accumulation and foam cell formation.30,31
The magnitude of intimal vascularization has also been
considered to be an additional feature of unstable
plaques,32 which exhibit larger and more irregular vessels
than stable plaques.33 Similar to the human condition,
disrupted intralesional vessels in angiotensin II–treated
mice are the most likely source of plaque hemorrhage.
Although angiotensin II signaling is involved in path-
ways that stimulate SMC migration and proliferation,16,34
it is still not clear how angiotensin II affects the relative
contribution of SMCs to the lesion composition. In our
study, angiotensin II–treated arteries also displayed thicker
muscular layers, especially in lesions that contained in-
traplaque hemorrhage/hemosiderin. In addition to the
direct actions of angiotensin II on SMC proliferation,34
other mechanisms, such as hemorrhage-/inflammation-
induced proliferation, should be considered. For instance, a
higher incidence of SMC proliferation and hemosiderin-
laden macrophages has been found in lesions from patients
with unstable, but not stable, angina. Therefore, the thick-
ened muscular layer in angiotensin II–treated arteries may
be a healing posthemorrhage process rather than an indica-
loproteinase (MMP)-2 levels in homogenates of ligated
e. Bars represent mean  SEM; *P  .05. B, MMP-2
entative sections of ligated carotid arteries from control




reas otor of plaque stability.
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into lipid-laden macrophages play a pivotal role in matrix
degradation, plaque destabilization, and atherosclerotic re-
modeling. In vulnerable plaques, MMPs secreted by macro-
phages/foam cells digest the matrix components within the
fibrous cap.35,36 The presence of MMP-rich macrophages
represents a histologic marker of expansively remodeled arter-
ies whose plaques are vulnerable to rupture.13 Therefore, we
attempted to demonstrate macrophage/foam cell activation
by assessing the activity of MMP-2, a recognized mediator of
macrophage-induced plaque rupture.36 Our results showed a
twofold increase in the content of active MMP-2 per unit of
tissue weight in the arteries from angiotensin II–treated mice.
Preferential localization of MMP-2 in foam cell–rich areas is
consistent with previous studies showing that macrophage
foam cells producemoreMMPs than non–lipid-ladenmacro-
phages.37 Because our results do not suggest a change in the
proportion of foam cells or macrophage staining in the intima
of angiotensin II–treated compared with control mice, we
hypothesize that increased macrophage/foam cell activation
accounts for the increasedMMP-2 production in angiotensin
II–treated arteries. In agreement, Sakamoto et al9 observed
that the administration of angiotensin II to apoE-KO mice
increased the percentage of macrophage foam cells expressing
a class A scavenger receptor, a glycoprotein involved with
oxidized low-density lipoprotein uptake. Because double
staining for MMP-2 and -actin was not performed in this
study, we could not exclude the possibility that SMCs are an
additional source of MMP-2 in these lesions.
Inflammation, a key component of atherosclerosis, is ini-
tiated and sustained by a complex interplay among a variety of
mediators regulating endothelial activation, monocyte che-
moattraction, macrophage retention, and differentiation.
Among these mediators, the chemokine MCP-1 and the
endothelial-derived adhesion molecule VCAM-1 are known
to be early responders to atherosclerosis-inducing stimu-
li.25,38 More importantly, sustained production of MCP-1
and VCAM-1 could provide further lesion progression to an
unstable form: ie, “inflamed” lesions evolve to unstable
plaques. Not surprisingly, the production of both agents was
significantly higher in ligated arteries from angiotensin II–
treated mice. Intralesional activated macrophages/foam cells
and endothelial cells are, respectively, most likely the sources
of MCP-1 and VCAM-1 at this stage of lesion develop-
ment.7,39 One should also consider some synergism between
angiotensin II and hypercholesterolemia in inducing SMCs to
undergo a phenotypic change to an inflammatory phenotype.
Angiotensin II is known to induce MCP-1 and nuclear
factor-	 B in cultured SMCs,25 and cholesterol per se
induces SMC transdifferentiation to a macrophage-like
state.40 Likewise, further studies are needed to address this
possibility, as well as whether the inflammatory-type SMC
has an impaired ability to synthesize collagen. It is clear,
however, from our study that a sustained elevation of
chemokine/adhesion molecule production would result in
continued inflammatory cell chemoattraction. The pres-
ence of intralesional microvessels certainly facilitates thecontinued access of inflammatory cells within lesions, espe-
cially the large ones.
Previous studies have postulated that the nature of the
remodeling process in atherosclerotic plaques helps in the
differentiation between stable and unstable lesions.11 Because
of the limitations of animal models in mimicking the human
condition, we believe that introducing this parameter to the
analysis of experimental plaques is a crucial step. One of the
most important findings in our study was the positive corre-
lation between intimal area and vessel expansion in both
control and angiotensin II–treated mice. In addition to con-
firming the results by Ivan et al,14 demonstrating a close
relationship between intimal inflammation and expansive re-
modeling in ligated arteries of apoE-KO mice, our results
show that this model can be effectively used to assess the role
of individual atherogenic/antiatherogenic agents on markers
of plaque stability. It would be expected that as the lesion
increases in size, an equal fraction of lumen areawould be lost.
However, such an inverse relationship was not shown by
correlation analysis, thus confirming studies with human ath-
erosclerotic vessels.41
Another important aspect is that the development of
adventitial proliferationwas further accelerated by angiotensin
II. Although adventitial inflammation may play a role in
plaque progression,42 in our study, a correlation was not
found between adventitial area and vessel expansion (data not
shown), thus confirming the notion that this remodeling
mode is dependent on intimalmacrophage/foam cell activity.
In summary, our data show that angiotensin II promotes
markers of plaque instability by inducing neovascularization,
hemorrhage, and inflammation, and this is accompanied by
further expansive remodeling. Additionally, our data further
strengthen the concept that expansively remodeled plaques
represent an unstable phenotype.
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